



Investor Presentation

September 2018

TherapeuticsMD[®]

For Her. For Life.

TherapeuticsMD.com

Forward-Looking Statements

This presentation by TherapeuticsMD, Inc. (referred to as “we” and “our”) may contain forward-looking statements. Forward-looking statements may include, but are not limited to, statements relating to our objectives, plans and strategies, as well as statements, other than historical facts, that address activities, events or developments that we intend, expect, project, believe or anticipate will or may occur in the future. These statements are often characterized by terminology such as “believe,” “hope,” “may,” “anticipate,” “should,” “intend,” “plan,” “will,” “expect,” “estimate,” “project,” “positioned,” “strategy” and similar expressions and are based on assumptions and assessments made in light of our managerial experience and perception of historical trends, current conditions, expected future developments and other factors we believe to be appropriate.

Forward-looking statements in this presentation are made as of the date of this presentation, and we undertake no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties, many of which may be outside of our control. Important factors that could cause actual results, developments and business decisions to differ materially from forward-looking statements are described in the sections titled “Risk Factors” in our filings with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as our current reports on Form 8-K, and include the following: whether the FDA will approve the NDA for our TX-001HR product candidate and whether such approval will occur by the PDUFA target action date; our ability to maintain or increase sales of our products; our ability to develop and commercialize our hormone therapy drug candidates and one-year contraceptive vaginal system licensed product and obtain additional financing necessary therefor; whether we will be able to comply with the covenants and conditions under our term loan agreement; the length, cost and uncertain results of our clinical trials; potential of adverse side effects or other safety risks that could preclude the approval of our hormone therapy drug candidates or adversely affect the commercialization of our current or future approved products; the ability of our licensees to commercialize and distribute our product and product candidates; our reliance on third parties to conduct our clinical trials, research and development and manufacturing; the availability of reimbursement from government authorities and health insurance companies for our products; the impact of product liability lawsuits; the influence of extensive and costly government regulation; the volatility of the trading price of our common stock; and the concentration of power in our stock ownership.

TX-001HR, TX-005HR, and TX-006HR are investigational drugs and are not approved by the FDA. This non-promotional presentation is intended for investor audiences only.

TherapeuticsMD, A Premier Women's Health Company

Annovera™

 vitaMedMD®

Annovera™

TX-001HR*

 Imvexxy™
(estradiol vaginal inserts)
4 mcg - 10 mcg




CONTRACEPTION

PRENATAL CARE

CONTRACEPTION/
FAMILY PLANNING -
PERIMENOPAUSE

VASOMOTOR
SYMPTOMS

DYSPAREUNIA
(Vulvar &
Vaginal Atrophy)



REPRODUCTIVE HEALTH

MENOPAUSE MANAGEMENT

*Investigational product, pending FDA approval

TherapeuticsMD®

For Her. For Life.

Seasoned Management Team with a Proven Track Record of Commercial Execution



Tommy Thompson
Chairman of the Board

- Former US Secretary of Health and Human Services (2001-2005)
- Holds multiple board memberships, including Centene and United Therapeutics
- 40-year public health career



Angus Russell
Board Member

- Former Chief Executive Officer and Chief Financial Officer of Shire PLC
- Former Vice President of Corporate Finance at AstraZeneca
- Holds multiple board memberships, including Chairman of Revance Therapeutics



J. Martin Carroll
Board Member

- Former President and Chief Executive Officer of Boehringer Ingelheim (US)
- Former EVP of Customer Marketing and Sales of US Human Health at Merck
- Holds multiple board memberships, including Catalent




Jane Barlow
Board Member

- 25 years of clinical and strategic healthcare experience
- Former Chief Medical Officer of CVS Health's Medicare and Government Services
- Former Vice President of Clinical Innovation at MEDCO Health Solutions



Robert Finizio
CEO, Co-Founder, and Director

- Co-founded vitaMedMD in 2008
- Co-founded CareFusion (Sold to Cardinal Health in 2006)
- 22 years of experience in early stage healthcare company development



Brian Bernick, MD
Co-Founder and Director

- Co-founded vitaMedMD in 2008
- 25 years of experience in healthcare/women's health
- Past OBGYN Department Chair - Boca Raton Regional Hospital
- Past ACOG Committee Member
- OBGYN – trained University of Pennsylvania



John Milligan
President

- Co-founded CareFusion
- Held executive sales and operation management positions at McKesson, Cardinal, and Omnicell
- 20+ years of operations experience



Dan Cartwright
Chief Financial Officer

- Former CFO of American Wireless, Telegeography, and WEB Corp
- Participated in American Wireless/Arush Entertainment merger
- Former KPMG and PricewaterhouseCoopers accountant



Sebastian Mirkin, M.D.
Chief Medical Officer

- Former Clinical Lead of Women's Health at Pfizer
- 15+ years of experience developing women's health products
- Reproductive endocrinologist & infertility specialist



Dawn Halkuff
Chief Commercial Officer

- 20+ years of commercial and marketing experience
- SVP of the Pfizer Consumer Healthcare Wellness Organization
- Commercial lead for sales and marketing of the Pfizer Women's Health Division



Julia Amadio
Chief Product Officer

- 25+ years of women's health pharmaceutical experience
- Product development leader for J&J, Wyeth, Aventis, and others
- Worked on development of Prempro®, Premphase®, and Estalis®



Christian Bloomgren
VP, Sales

- 16+ years of experience in the pharmaceuticals and biotech
- Created a national sales channel, led the Specialty Diagnostics business at ViaCell, Inc.
- Product launch and sales management roles at Eli Lilly & Company and KV Pharmaceutical

Insiders own approximately ~21% of total outstanding shares

TherapeuticsMD®

For Her. For Life.

Responsible and Financially Disciplined Approach to Delivering Results







- TXMD has a 10 year history of delivering strong results in a financially efficient manner
- We have two recent product approvals (Imvexxy and Annovera) and a PDUFA target action date for TX-001HR of October 28, 2018
- We remain well-financed, including our flexibility of having an additional \$125M through our term loan with MidCap Financial
 - \$75M on approval and first commercial sale of TX-001HR on or before May 31, 2019
 - Additional \$50M on hitting Imvexxy and TX-001HR 12 month net revenue threshold on or before December 31, 2019
- The next phase of growth is expected to be through promotion and sales of Imvexxy, Annovera and TX-001HR, if approved

Track Record of Execution

Date	Milestone/ Catalyst
3/14/13	First Registered Equity Offering
8/5/13	Commenced Phase 3 Replenish Trial of TX-001HR
9/29/14	Commenced Phase 3 Rejoice Trial of TX-004HR (Imvexxy)
12/7/15	Positive Top-Line Results from Phase 3 Rejoice Trial of TX-004HR (Imvexxy)
7/7/16	Submission of New Drug Application for Imvexxy
12/5/16	Positive Top-Line Results from Phase 3 Replenish Trial of TX-001HR
12/28/17	Submission of New Drug Application for TX-001HR
5/29/18	Received FDA Approval of New Drug Application for Imvexxy
7/31/18	Acquired US Rights to Annovera from the Population Council
7/31/18	Entered into Strategic Partnership with Knight Therapeutics for Imvexxy and TX-001HR
8/6/18	Commenced US Commercial Launch of Imvexxy
8/10/18	Received FDA Approval of New Drug Application for Annovera
10/28/18	PDUFA Date for TX-001HR – Potential to have Three Approved Drugs in One Year

Total of 241 global patent applications with 22 issued foreign patents and 20 issued U.S. patents for Imvexxy and TX-001HR

Women's Health Assets With Large Total Addressable Market Opportunities

	 	 	 
Indication	Females to prevent pregnancy	Moderate to severe vasomotor symptoms (VMS) due to menopause*	Moderate to severe dyspareunia, a symptom of VVA, due to menopause
Condition Description	Contraception	VMS due to Menopause	VVA due to Menopause
Active Ingredients	Segesterone Acetate/ Ethinyl Estradiol	Bio-Identical 17 β -Estradiol + Bio-Identical Progesterone	Bio-Identical 17 β -Estradiol
Form	Vaginal System	Oral softgel capsule	Vaginal softgel insert
Key Value Proposition	First and only patient-controlled, procedure-free, long-acting, reversible birth control product	Potential first and only bio-identical FDA-approved combination product	Easy to use, lowest approved dose, designed to support patient adherence
Affected US Population	43 million women ¹	36 million women ³	32 million women ^{5,6}
US TAM Opportunity	\$5B ²	>\$25B ^{4,7}	>\$20B ⁷
Status	Approved Aug. 10, 2018 Commercial Launch: Est. 4Q19-1Q20	PDUFA Target Action Date: Oct. 28, 2018	Approved May 29, 2018 Commercial Launch: August 2018

* Potential indication; pending FDA approval

1) Contraceptive Use in the United States, Guttmacher, July 2018. IQVIA Patient Tracker.

2) QuintilesIMS MIDAS, QuintilesIMS Analysis, Company filings. Long acting reversible contraceptive market includes: Nexplanon/Implanon, Mirena family, Paragard and Liletta. Net sales as reported in company filings.

3) Derived from U.S. Census data on women in the age group who normally experience symptoms.

4) Based on pre-WHI annual scripts of FDA-approved HT products.

5) The North American Menopause Society. Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society. *Menopause*. 2013;20(9):888-902.

6) Gass ML, Cochrane BB, Larson JC, et al. Patterns and predictors of sexual activity among women in the hormone therapy trials of the Women's Health Initiative. *Menopause*. 2011;18(11):1160-1171.

7) Based on market pricing of current FDA-approved HT products.

TherapeuticsMD[®]

For Her. For Life.



Imvexxy™

(estradiol vaginal inserts)

4 mcg • 10 mcg

Approved for the treatment of moderate-to-severe dyspareunia (vaginal pain associated with sexual activity), a symptom of vulvar and vaginal atrophy (VVA), due to menopause.

Vulvar and Vaginal Atrophy (VVA) Program

TherapeuticsMD®

For Her. For Life.

Invexxy Key Timeline

- 10 mcg national launch started on August 6, 2018
- 4 mcg commercially available on September 13, 2018
- Bio-Ignite went live August 10, 2018 with 12 pharmacies ordering Invexxy

Imvexxy Launch Update

as of September 19, 2018

- Over 10,700 units (scripts) of Imvexxy have been dispensed by pharmacies and paid for by over 6,900 patients*
 - 8,650 - maintenance packs
 - 2,050 - starter packs
- 78% of patients are enrolled in commercial insurance with 11% currently being able to be adjudicated based on current insurance coverage for Imvexxy
- 44% of patients received their 2nd paid refill
- Average patient has an additional 10 authorized refills on the maintenance pack
- Over 3,400 prescribers have written a prescription for Imvexxy

*Based on utilization of our affordability programs. Cash pay or covered by insurance.
98% of patients paid an out of pocket copay between \$15 to \$35 to fill their prescription.

TherapeuticsMD®

For Her. For Life.

Update on Insurance Coverage

- ~36% unrestricted commercial coverage (no step edits and no PA) as of September 19, 2018
 - TXMD will start to see the financial benefit of coverage and incremental increase in net revenue approximately 90 days following gaining commercial coverage
 - Net revenue for Imvexxy is expected to peak at ~60% when insurance coverage is fully established
- Top 3 FDA-approved VVA products (Estrace, Premarin and Vagifem) top out at 65%+ unrestricted commercial coverage
 - Not including Medicare Part D which comprises 25% of script volume

Net Revenue Ramp for Commercially Insured Patients

- TXMD already working to achieve prescriber and patient adoption, prior to full commercial insurance coverage
- The 90 day lag in commercial payer reimbursement will have a short-term negative impact on net revenue due to TXMD affordability programs
- As the patient base becomes covered by commercial insurance, TXMD expects net revenue to be on average 60% of WAC
- Commercial insurance coverage for Imvexxy expected to be fully established by 4Q 2019
 - Product mix during this growth phase currently expected to be two starter packages for every three maintenance packages
 - Starter pack:
 - WAC \$405
 - 60% net = \$243 average net revenue per unit (script)*
 - Maintenance pack:
 - WAC \$180
 - 60% net = \$108 average net revenue per unit (script)*
 - Blended starter/maintenance expected
 - Avg. WAC \$270**
 - 60% net = \$162 net revenue per unit (script)*
- With fully established coverage, we expect Imvexxy to support our goal of reaching profitability

*Estimated net revenue for a script with commercial reimbursement, which accounts for wholesaler distribution cost, payer discounts and patient savings program.


**Based on product mix during growth phase, which is expected to be two starter packs to every three maintenance packs.

TherapeuticsMD[®]

For Her. For Life.

Relationship of Commercial Lives Covered Versus Imvexxy Covered Claims and Realized Net Revenue

Trendline in chart based on TXMD historical experience and other products



* No net revenue generation today. TXMD will start to see the financial benefit of coverage and incremental increase in net revenue approximately 90 days following gaining commercial coverage.

**GTN in 1Q 2019 impacted by insurance plan resets

References:

1. MMIT

TherapeuticsMD®

For Her. For Life.

Variables Impacting Net Revenue Ramp

Top Targets	
Top 10 Commercial Payers	Percentage of Total Lives Covered*
Express Scripts	15.5%
CVS Caremark	14.6%
Prime	8.2%
Anthem	7.7%
United	7.7%
OptumRx	5.9%
Aetna, Inc.	5.1%
CIGNA Health Plans Inc.	4.1%
Kaiser Foundation Health Plans	4.0%
Blue Cross Blue Shield	2.9%


- Achieving 60% net revenue assumes access to top 10 commercial payers by 4Q 2019
- Recently achieved ~67% unrestricted commercial access with Express Scripts and ~93% with Anthem
- We are in various stages of the negotiation process with the other top 10 commercial payers
- Emphasis on payers with patients in our top VVA prescribing states of Florida, Texas and California

Vulvar and Vaginal Atrophy (VVA)

- A component of genitourinary syndrome of menopause (GSM)
- **Chronic** and **progressive** condition that results from decreased estrogen levels characterized by thinning of vaginal tissue
- Diagnosed in approximately **50%** of postmenopausal women¹
- Primary symptom = dyspareunia (painful intercourse)
- Secondary symptoms include: vaginal dryness, itching, irritation, bleeding with sexual activity, dysuria, urgency, frequency, recurrent UTIs, and incontinence
- Current treatments include: prescription hormone creams, tablets, and rings in addition to over-the-counter lubricants


HEALTHY VAGINAL TISSUE

- Thick
- Moist
- High estrogen level
- Low pH (<5)
- Increased superficial cells (>15%)
- Decreased parabasal cells (<5%)



ATROPHIC VAGINAL TISSUE

- Thin
- Dry
- Low estrogen level
- High pH (>5)
- Decreased superficial cells (<5%)
- Increased parabasal cells (>30%)



1) Kingsberg, Sheryl A., et al. "Vulvar and Vaginal Atrophy in Postmenopausal Women: Findings from the REVIVE (REal Women's Views of Treatment Options for Menopausal Vaginal ChangEs) Survey." International Society for Sexual Medicine 2013, no. 10, 1790-1799.

Current US VVA Market Overview

32M with VVA symptoms (1 out of 2 menopausal women) in the United States^{1,2}

50% (16M)
seek treatment for VVA⁴
- 25% (8M) OTC products
- 18% (5.7M) past HT users
- 7% (2.3M) current HT users

Only 7% (2.3M) are
current users of
Rx hormone
therapy³

- Only 7% of women (2.3M) with VVA symptoms, are currently being treated today with Rx hormone therapy (HT)³
 - Long-term safety concerns⁵
 - Efficacy⁵
 - Messiness⁵
 - Need for applicator⁵

1) The North American Menopause Society. Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society. *Menopause*. 2013;20(9):888–902.

2) Gass ML, Cochrane BB, Larson JC, et al. Patterns and predictors of sexual activity among women in the hormone therapy trials of the Women's Health Initiative. *Menopause*. 2011;18(11):1160–1171.

3) Kingsberg SA, Krychman M, Graham S, Bernick B, Mirkin S. The Women's EMPOWER Survey: Identifying women's perceptions on vulvar and vaginal atrophy and its treatment. *J Sex Med*. 2017;14:413–424; IMS Health Plan Claims (April 2008–Mar 2011).

4) TherapeuticsMD "EMPOWER" Survey, 2016

5) Wysocki, S et al, Management of Vaginal Atrophy: Implications from the REVIVE Survey. *Clinical Medicine Insights: Reproductive Health* 2014;8 23-30 doi:10.4137/CMRH.S1449

TherapeuticsMD[®]

For Her. For Life.

Professional Societies and FDA Recommend the Lowest Effective Dose



American College of Obstetricians and Gynecologists (ACOG)¹

“Low-dose and ultra-low systemic doses of estrogen may be associated with a better adverse effect profile than standard doses and may reduce vasomotor symptoms in some women.”



North American Menopause Society (NAMS)²

“The lowest dose of HT should be used for the shortest duration needed to manage menopausal symptoms. Individualization is important in the decision to use HT and should incorporate the woman’s personal risk factors and her quality-of-life priorities in this shared decision.”



FDA³

“...this guidance encourages sponsors to develop the lowest doses and exposures for both estrogens and progestins for indications sought, even though specific relationships between dose, exposure, and risk of adverse events may not be known.”

References: 1. ACOG Practice Bulletin No. 141: management of menopausal symptoms. *Obstet Gynecol.* 2014;123(1):202-216. 2. The North American Menopause Society. Clinical care recommendations chapter 8: prescription therapies. <http://www.menopause.org/publications/clinical-care-recommendations/chapter-8-prescription-therapies>. Accessed March 8, 2018. 3. Food and Drug Administration. Guidance for Industry – Estrogen and Estrogen/Progestin Drug Products to Treat Vasomotor Symptoms and Vulvar and Vaginal Atrophy Symptoms—Recommendations for Clinical Evaluation. <https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm071643.pdf>. Published January 2003. Accessed March 8, 2018.

TherapeuticsMD[®]

For Her. For Life.

Imvexxy is “Redefining Relief”

Owning clinical attributes with the underpinning of a highly effective patient experience

Key Clinical Attributes:

- 1 New lowest approved dose
- 2 Strong efficacy and safety data
- 3 Improvement seen at week 12 (primary) and as early as 2 weeks (secondary)
- 4 PK data where systemic hormone levels remain within normal postmenopausal range

Key Physical Attributes:

- 5 Ease of use and absence of applicator
- 6 Ability to be used any time of day
- 7 A mess-free way to administer
- 8 Dose packaging to optimize patient compliance and enhance provider and patient acceptance

FOR WOMEN WITH MODERATE TO SEVERE DYSPARIA, A SYMPTOM OF VULVAR AND VAGINAL ATROPHY DUE TO MENOPAUSE


DISCOVER A TREATMENT EXPERIENCE WITH

SIMPLICITY AT ITS CORE¹

COMFORTABLE, CONVENIENT, APPLICATOR-FREE ADMINISTRATION²

AN ELEGANT DESIGN THAT SIMPLY FITS INTO HER LIFE³

THE ONLY ULTRA-LOW-DOSE VAGINAL ESTRADIOL AVAILABLE IN BOTH 4-MCG AND 10-MCG DOSES⁴



Imvexxy
(estradiol vaginal insert)
4mg/11mg

IMPORTANT SAFETY INFORMATION

WARNINGS: ENDOMETRIAL CANCER, CARDIOVASCULAR DISORDERS, BREAST CANCER AND PROBABLE DEMENTIA
See full prescribing information for complete boxed warning.

Estrogen-Only Therapy

- There is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogen
- Estrogen-alone therapy should not be used for the prevention of cardiovascular disease or dementia
- The Women's Health Initiative (WHI) estrogen-alone study reported increased risks of stroke and deep vein thrombosis (DVT)
- The WHI Memory Study (WHIMS) estrogen-alone ancillary study of WHI reported an increased risk of probable dementia in postmenopausal women 65 years of age and older

Estrogen Plus Progestin Therapy

- Estrogen plus progestin therapy should not be used for the prevention of cardiovascular disease or dementia
- The WHI estrogen plus progestin study reported increased risks of stroke, DVT, pulmonary embolism (PE) and myocardial infarction (MI)
- The WHI estrogen plus progestin study reported increased risks of invasive breast cancer
- The WHIMS estrogen plus progestin ancillary study of WHI reported an increased risk of probable dementia in postmenopausal women 65 years of age and older

Please see additional Important Safety Information on the reverse side and the Full Prescribing Information, including the Boxed Warning, in packet.


TherapeuticsMD[®]

For Her. For Life.

Foundation Built for a Strong Launch

TXMD Sales Force in OB/GYN Offices

- 40% overlap with current prenatal vitamins business
- Sales force of 150
- Partnership with inVentiv, leading contract sales organization
- Operational and analytic systems



 =TXMD territories

TherapeuticsMD®

For Her. For Life.















Current FDA-Approved VVA Products

Local estrogen therapy currently represents over 95% market share in the VVA market

- Current standard of care per medical society guidelines
- Current poor compliance within the class
- Imvexxy is the new lowest approved dose with potential for improved compliance

30-day WAC Maintenance dose pricing \$180 for IMVEXXY

- Near parity w/ Vagifem (\$170.16) & less than newest entrants Intrarosa (\$198.75), Ospheña (\$203.80)

Product	Estrace® Cream (estradiol vaginal cream, USP, 0.01%) ¹	Premarin Cream® (conjugated estrogens) ²	Estring® (estradiol vaginal Ring) ³	Vagifem® (estradiol vaginal inserts) ⁴	IMVEXXY (estradiol vaginal inserts) ^{5,6}	Intrarosa® (prasterone vaginal inserts) ⁷	Ospheña® (ospemifene tablets) ⁸
							
							
FDA approval	1984	1978	1996	1999	2018	2016	2013
Active Ingredient	100µg estradiol	625 µg conjugated equine estrogens	2,000 µg estradiol	10µg estradiol	4 µg or 10 µg estradiol	6,500 µg prasterone	60,000 µg ospemifene
TRx MSB Dollars 2017 ⁹	\$504,804,770	\$463,264,428	\$105,169,311	\$446,044,670	-	\$3,597,519	\$66,904,883
Method of administration	Vaginal Cream	Vaginal Cream	Vaginal Ring	Tablet Vaginal Insert	Softgel Vaginal Insert	Vaginal Insert	Oral Tablet
WAC package price (2018) ¹⁰	\$314.87 (42.5-g tube)	\$355.77 (30-g tube)	\$431.34 (1 ring)	\$170.16 (8 tablets)	\$180.00 (8 inserts)	\$185.50 (28 inserts)	\$611.39 (90 tablets)
Calculated WAC 30-day supply (2018) ¹⁰	\$104.96	\$118.59	\$143.78	\$170.16	\$180.00	\$198.75	\$203.80


← Local Vaginal Estrogen > 95% Market Share →

There have been no head-to-head trials between IMVEXXY and any of the products listed above. All trademarks are the property of their respective owners. Abbreviations: WAC, wholesale acquisition cost.

References: 1. Estrace Vaginal Cream [package insert]. Irvine, CA: Allergan USA, Inc.; 2017. 2. Premarin Vaginal Cream [package insert]. Philadelphia, PA: Wyeth Pharmaceuticals Inc., a subsidiary of Pfizer Inc.; 2017. 3. Estring [package insert]. New York, NY: Pharmacia & Upjohn Company LLC, a subsidiary of Pfizer Inc.; 2017. 4. Vagifem [package insert] Plainsboro, NJ: Novo Nordisk Inc.; 2017. 5. IMVEXXY [package insert] Boca Raton, FL: TherapeuticsMD, Inc.; 2018. 6. Constantine GD, Simon JA, Pickar JH, et al. The REJOICE trial: a phase 3 randomized, controlled trial evaluating the safety and efficacy of a novel vaginal estradiol soft-gel capsule for symptomatic vulvar and vaginal atrophy. *Menopause*. 2017;24(4):409-416. 7. Intrarosa [package insert]. Waltham, MA: AMAG Pharmaceuticals, Inc.; 2017. 8. Ospheña [package insert]. Florham Park, NJ: Shionogi Inc.; 2015. 9. Symphony Health Solutions PHAST Data powered by IDV; Annual 2017 [a. [2017 Estrace and generics (Teva, Mylan, Impax & Alvogon) and 2017 Vagifem, Yuvafem (authorized generic of Vagifem), and Teva generic]. 10. Price RX March 2018.

TherapeuticsMD®
For Her. For Life.

Payer Breakdown of FDA-Approved VVA Products¹



- As of September 19, 2018, Imvexxy achieved ~36% unrestricted commercial coverage (no step edits or PA)
 - Expect commercial coverage to peak at 60%+
- Earliest expected Medicare Part D coverage for Imvexxy would be January 1, 2019
- Historical trends show recent launch of Intrarosa getting to ~65% unrestricted commercial access 9 months after field launch²

¹MMIT Data April 2018

²MMIT

VVA Class Commercial Coverage:¹

Top 25 payers represent ~87% of Commercial lives with a majority of access unrestricted

Vulvar and Vaginal Atrophy- 184,277,713 Commercial Lives		% of Commercial lives	Estrace Cream	Intravaginal	Osphena	Premarin Cream	Vagifem	Yuvaferm	Estring
Controlling Payer/PBM	Lives								
Express Scripts PBM	28,507,971	15%	Covered	Covered	Covered	Preferred	Covered	Preferred	Preferred
CVS Caremark RX	27,256,869	15%	Preferred	Covered	Preferred	Preferred	Preferred	Covered	Preferred
Anthem, Inc.	14,385,833	8%	Covered	Covered (PA/ST)	Covered (PA/ST)	Preferred	Covered	Preferred	Covered
UnitedHealth Group, Inc.	13,571,816	7%	Covered	Covered	Covered	Covered	Covered	Preferred	Preferred
OptumRx	11,762,164	6%	Preferred	Covered	Covered	Preferred	Covered	Preferred	Covered
Aetna, Inc.	7,903,792	4%	Covered	Covered	Covered	Preferred	Covered	Preferred	Covered
Kaiser Foundation Health Plans, Inc.	7,453,024	4%	Preferred	Not Covered	Not Covered	Preferred	Not Covered	Not Covered	Preferred
CIGNA Health Plans, Inc.	7,408,428	4%	Covered	Covered	Covered	Preferred	Covered	Preferred	Preferred
Department of Defense - TRICARE	7,036,804	4%	Preferred	Preferred (PA/ST)	Preferred	Preferred	Preferred (PA/ST)	Preferred	Preferred
Blue Cross Blue Shield Association Corporation	5,410,238	3%	Preferred	Covered	Covered	Preferred	Covered	Covered	Covered
Health Care Service Corporation	5,290,357	3%	Preferred	Covered	Covered	Covered	Covered	Preferred	Covered
Department of Veterans Affairs (VHA)	4,777,557	3%	Covered (PA/ST)	Covered (PA/ST)	Covered (PA/ST)	Preferred	Covered (PA/ST)	Covered (PA/ST)	Covered (PA/ST)
Envision Pharmaceutical Services	3,125,237	2%	Covered	Covered	Covered	Preferred	Covered	Generic (Preferred)	Covered
Indian Health Service (IHS)	2,186,820	1%	Covered (PA/ST)	Covered (PA/ST)	Covered (PA/ST)	Preferred	Covered (PA/ST)	Covered (PA/ST)	Covered (PA/ST)
Blue Shield of California	1,840,474	1%	Covered	Covered (PA/ST)	Covered (PA/ST)	Preferred	Covered	Preferred	Preferred
CareFirst, Inc.	1,517,895	1%	Covered	Covered	Preferred	Preferred	Covered	Covered	Preferred
EmblemHealth, Inc.	1,477,204	1%	Covered	Covered	Covered	Preferred	Covered	Preferred	Preferred
Blue Cross Blue Shield of Michigan	1,399,562	1%	Covered	Covered	Covered	Preferred	Covered	Covered	Preferred
Humana, Inc.	1,212,751	1%	Covered	Not Covered	Not Covered	Not Covered	Not Covered	Not Covered	Covered
Blue Cross and Blue Shield of Florida, Inc.	1,207,374	1%	Covered	Covered	Covered	Preferred	Preferred	Preferred	Covered
Blue Cross Blue Shield of Minnesota	1,173,171	1%	Preferred	Covered	Covered	Covered	Covered	Preferred	Covered
State of New York	1,092,511	1%	Preferred	Not Covered	Preferred	Preferred	Covered	Covered	Covered
Blue Cross Blue Shield of North Carolina	1,061,152	1%	Covered	Covered	Covered	Preferred	Covered	Preferred	Covered
Centene Corporation	1,012,171	1%	Covered (PA/ST)	Not Covered	Covered	Preferred	Covered (PA/ST)	Covered	Covered
Blue Cross Blue Shield of Alabama	991,169	1%	Preferred	Covered	Covered	Covered	Preferred	Not Covered	Covered

References:

1. MMIT May 2018

TherapeuticsMD[®]

For Her. For Life.

Favorable Payer Dynamics: No Substitution Across Branded Products

Case Study: Vagifem[®] Generics Launch

- Yuvaferm launch in October 2016

	VVA TRx Market Share (%) Oct 2015-Sept 2016	VVA TRx Market Share (%) Oct 2016-April 2018	Gains (Losses)
Vagifem	29.7%	5.4%	-24.3%
Generic Estradiol Tablets (including Yuvaferm and others)	-	24.4%	24.4%
Total	29.7%	29.8%	0.1%

- Yuvaferm continues to take market share from only Vagifem
- No substitution or cannibalization of other branded products

Prior Authorization Example in the VVA Class

- The majority of commercial payers do not require PA/ST for branded VVA treatments today¹
- However, select payers require written PA and step-through one or two preferred products in select cases
 - Unlikely for Imvexxy to step-edit through a higher dose vaginal estrogen product
- Low dose vaginal estrogen remains frontline therapy

Example 1: PA Criteria for Osphena at Anthem²

8. APPROVAL CRITERIA: CHECK ALL BOXES THAT APPLY

NOTE: Any areas not filled out are considered not applicable to your patient & MAY AFFECT THE OUTCOME of this request.

- | | | |
|------------------------------|-----------------------------|---|
| <input type="checkbox"/> Yes | <input type="checkbox"/> No | Patient is female |
| <input type="checkbox"/> Yes | <input type="checkbox"/> No | Patient has a diagnosis of moderate-to-severe dyspareunia due to vulvar and vaginal atrophy (VVA) associated with menopause |
| <input type="checkbox"/> Yes | <input type="checkbox"/> No | Patient has had a trial of, or insufficient response to one preferred vaginal estrogen product (that is, Premarin vaginal cream, Vagifem, or Femring) |


References:

1. MMIT, May 2018
2. Anthem. https://www11.anthem.com/provider/noapplication/f0/s0/t0/pw_e213344.pdf?na=pharminfo

TherapeuticsMD[®]

For Her. For Life.

Recent VVA TRx Launch Trajectories Represent Reasonable Comparators for Invexxy Launch in Year 1



Rate Limited Factors in Year 1 that Impact Launch:

- Limited number of new women going onto therapy each year
- Number of women that switch to a new product year 1
- The impact of the above factors is reduced in years 2 and beyond

References:
1. PHAST Symphony

TherapeuticsMD®

For Her. For Life.

TXMD's Patient Engagement Programs for Adoption, Affordability & Adherence



- Developed over the past 6 years in an effort to improve the long term value of a patient through Education, Adherence and Co-Pay assistance
- TXMD utilizes standard pharmaceutical industry programs in a more coordinated and effective fashion – maximizing impact and results
- Program has achieved 78% utilization of the Co-Pay assistance program compared to an industry standard of 30%
- Created and piloted around the prenatal vitamin product line to enhance the launches of Imvexxy and TX-001HR (if approved)

Results of TXMD Prenatal Vitamin Adoption & Adherence Programs

Patient Adherence

Industry Avg: 2.5 of 9 months



TXMD Avg: 7 of 9 months

Prescriber Loyalty

Industry Avg: 30 prescriptions per physician per year



TXMD Avg: 71 prescriptions per physician per year

Data Insights

Industry Avg: 60 days



TXMD Avg: Real time Data

TherapeuticsMD[®]

For Her. For Life.

Compliance and Fills Per Year Drives Top-Line Revenue

Current VVA Market

Vaginal Creams:

Average:
1.5 Fills Per Year²



Estrace



Premarin

Reasons Women Stop

Messiness¹

Reusable Applicator¹

Long-term Safety¹

Dose Preparation by User Required³

Vaginal Tablets:

Average:
3.5 Fills Per Year²



Vagifem

Reasons Women Stop

Efficacy¹

Applicator¹

Long-term Safety¹

Systemic Absorption¹

Product	TRx Dollars ⁴	Patient Count ⁵	Patient Share ⁵
Estrace	\$583,612,698	900,618	41%
Premarin	\$533,386,029	696,125	32%
Vagifem/Generics	\$525,321,410 ^a	448,745	20%

- Higher average fills per year enable Vagifem/Yuvafem to generate equal revenue as Premarin and Estrace with significantly less patients on therapy

1) Wysocki, S et al, Management of Vaginal Atrophy: Implications from the REVIVE Survey. *Clinical Medicine Insights: Reproductive Health* 2014;8 23-30 doi:10.4137/CMRH.S14498

2) Total Rx/Patient Count

3) The North American Menopause Society. Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society. *Menopause*. 2013;20(9):888-902.

4) Symphony Health Solutions PHAST Data powered by IDV; Annual 2017

a. 2017 Vagifem, Yuvafem (authorized generic of Vagifem), and Teva generic

5) IMS SDI's Total Patient Tracker; Annual 2017

Patient Engagement Program

Healthcare Provider Writes a Prescription



TXMD Affordability and Education Program



Affordability Program
Maximum Out-of-Pocket \$35



Retail Pharmacy Fills Prescription



Engagement Program to Increase
Compliance and Adherence

Start Saving Today!
Activate and download your e-card at savings.imvexxy.com
or
Text SAVE to 38745*

Imvexxy™
(estradiol vaginal inserts)
4 mg - 10 mcg

Savings Program
Pay \$35 or Less. Guaranteed.™

For coverage questions or cash paying customers
call 1-844-208-0002

The complex made simple,
cost-effective and stress free.

CONVENIENCE
We ensure your prescription is available for pick-up at your local pharmacy or delivered right to your door at no-additional charge.

SAVINGS
We see that your prescription is at the most affordable cost by:

- Verifying insurance coverage and optimizing benefits
- Offering access to manufacturer's affordability programs

SUPPORT
Pharmacists are standing by to answer questions and offer programs that help support your prescription therapy.

TherapeuticsMD®


For Her. For Life.

Incremental Fills Per Year Drive Upside to Net Revenues

Each incremental fill per year can add an estimated \$75M to Imvexxy net revenues

Year 5 Assumptions¹

Total VVA Patients on HT ²	2,300,000
Imvexxy Market Share	25 - 30%
Imvexxy Patients	665,000
WAC of Loading Dose	\$405.00
WAC of Maintenance Dose	\$180.00
Sum of Total Discounts per Rx	35%



¹Assumes zero market growth and zero price increases

²IQVIA Total Patient Tracker (2017 Data)

TherapeuticsMD[®]

For Her. For Life.

TX-001HR

Combination
Estrogen + Progesterone
(E+P) Program



TherapeuticsMD®

For Her. For Life.

TX-001HR Product Development Rationale


- 2002 Women's Health Initiative (WHI) study showed that the long-term use of certain *synthetic* hormones (a combination of medroxyprogesterone and conjugated equine estrogens) increased the risk of breast cancer, stroke, heart attack and blood clots (all FDA-approved combination hormonal products contain a synthetic Progestin and not a bio-identical Progesterone)
- 2002 Post WHI, women and healthcare providers shifted to Bio-Identical Hormone Therapy (BHRT) containing bio-identical estradiol and bio-identical progesterone as an alternative despite being *unapproved* drugs that are *not covered by insurance*



- Over 90M+ scripts of synthetic hormone therapy prescribed annually before 2002, declining to ~26M in 2015¹

- Today, patients have the choice between three therapies:

- FDA-approved, synthetic combination hormones
- FDA-approved, separate bio-identical hormone products
- Unapproved, compounded bio-identical hormones that have not been proven safe and effective, or covered by insurance



- Compounding filled the need for BHRT**
 - 30M scripts (3M women) of Compounded Bio-identical Hormone Therapy (CBHRT) prescribed annually in the U.S. currently^{2,3}

- All the major medical societies and the FDA discourage the prescribing of compounded hormones

- No FDA-approved BHRT bio-identical combination product of estradiol + progesterone



- If approved, TX-001HR would become the first and only FDA-approved bio-identical combination product to fill this unmet need

1) Symphony Health Solutions PHAST Data powered by IDV; Annual 2015
2) The reported number of annual custom compounded hormone therapy prescription of oral and transdermal estradiol and progesterones taken combined and in combination (26MM to 33MM)
3) Pinkerton, J.V. 2015. Menopause, Vol.22, No.9, pp 0-11.

TX-001HR – Potential Best in Class Therapy

TX-001HR

(If Approved)



Bio-Identical	✓
Single Dose Combination	✓
VMS Efficacy Data	✓
Endometrial Cancer Safety Data	✓
FDA-Approved	✓ ¹
Third-Party Reimbursement	✓ ²

Potential first and only:

- 1) Bio-identical combination estradiol & progesterone
- 2) FDA-approved

Dosing and Delivery

- Once-a-day single oral softgel capsule

Addresses Unmet Medical Need

- First and only combination of bio-identical estradiol and bio-identical progesterone product candidate
- Single combination dose option
- Positive Phase 3 Replenish Trial safety and efficacy results
- Potential third-party reimbursement, if approved

PDUFA target action date October 28, 2018

- Strong patent estate with patent expirations starting 2032

Benefits to women, healthcare providers, and pharmacies





1) NDA submitted December 28, 2017; FDA PDUFA date October 28th, 2018


2) Reimbursement anticipated if FDA-approved

TherapeuticsMD®

For Her. For Life.

Multi-Billion Dollar Total Substitutable Market Opportunity

TX-001HR Substitutable Market (if approved)	FDA-Approved		Compounded Combination Bio-Identical E+P
	Separate Bio-Identical E & P Pills	Combination Synthetic E+P ¹	
			
TRx US:	~3.8 million ¹	~3 million ²	12 – 18 million
TX-001HR Potential Substitutable Market	\$760M-\$950M ³	\$600M-\$750M ³	\$2.4B-\$4.5B ³
TX-001HR Total Substitutable Market Opportunity	<u>\$3.7B – \$6.1B</u>		

Separate Bio-Identical E & P Pills:	Product Use by Age	AGES 41-50	AGES 51-60	AGES 61-70	AGES 71+	TRx Totals
		<u>Progesterone</u>	903,680	1,596,847	902,733	399,665
	<u>Estradiol</u>	2,297,141	5,033,146	2,772,199	1,476,272	11,578,758 ¹

- **FDA-approved separate bio-identical estrogen and progesterone channel** alone represents up to \$950M annually at a WAC price of \$250
 - 2 separate copays
 - Not FDA approved to be used together for endometrial protection
- **Potential billion dollar opportunity with even only limited penetration into compounding channel**

1) Symphony Health Solutions PHAST Data powered by IDV; 12 months as of December 31 2017

2) Includes the following drugs: Activella®, FemHRT®, Angeliq®, Generic 17β + Progestins, Prempro®, Premphase®, Duavee®, Brisdelle®

3) Assume WAC pricing between \$200-250

All trademarks are the property of their respective owners.

TX-001HR Could Fulfill Therapeutic Gap For Stakeholders

Patients

- If approved, meet demand for bio-identical hormone therapy with a product approved by FDA on safety and efficacy
- Reduce of out-of-pocket costs via insurance coverage
- Convenience of one combination product
- Widely acceptable at pharmacies and not just compounding pharmacies

Healthcare Providers

- First and only FDA-approved bio-identical combination hormone therapy
- Clinically validated dose regimen
- Eliminate risks of compounded hormone therapy
- Meet patient demands and reduce patient out-of-pocket costs via insurance coverage
- Follow medical standards of care and society guidelines while reducing liability

Pharmacies

- Meet patient and physician demand for bio-identical hormone therapy
- Assuming third-party reimbursement, significantly improve net margin per script
- Lower certain legal and regulatory costs and risks

FDA/Regulatory Bodies

- Reduce need for and use of compounded hormone products
- Full enforcement of regulations regarding compounded hormones

BIO-IGNITE™

Compounding Pharmacy Partnership Strategy

BIO-IGNITE™ started as an outreach program to quantify the number of compounded bio-identical estradiol and progesterone prescriptions currently dispensed by the 3,000 high-volume compounding pharmacies, and qualify their interests in distributing our hormone product candidates, if approved.

WHAT IT HAS BECOME:

A four-phase strategic initiative to activate all current stakeholders involved in the BHRT community. Ensuring that TX-001HR has the best national access and uptake possible.



TherapeuticsMD®

For Her. For Life.

Bio-Identical Customization

Customization of therapy at compounding pharmacies refers to addressing the overall patient condition including menopausal symptoms, adrenal function, libido, energy levels, thyroid function and nutrition, rather than through micro-dose changes in estrogen/progesterone amounts based on blood levels

Estradiol & Progesterone Claims

Base for all Patients

Controls VMS symptoms
Promotes sleep & calming
Progesterone to oppose Estradiol - safety

Estrone, Estriol & DHEA Claims

Breast cancer reduction/prevention
Decrease clotting
Glucose maintenance
Improves lipids profile

Testosterone Claims

Libido
Muscle tone
Improves skin turgor
Emotional well-being

Thyroid (T3, T4) Claims

Weight gain
Lack of Energy
Depression
Memory

Supplements

Vitamin D3
Melatonin (sleep)
Omega-3

TX-001HR Doses

1 mg/100 mg

0.5 mg/100 mg

Covers >80% of Compounded E+P

Continued Testing
Blood, Saliva, Urine

TherapeuticsMD®

For Her. For Life.

BIO-IGNITE Progress and Results

Partnerships with Large Pharmacy Network and Individual Pharmacies

Pharmacy Network and Individual Pharmacy Partners

of Pharmacies

Combination Bio-Identical E+P Scripts

Artiria*

>300 Pharmacies In Network

~1,500,000 prescriptions annually

TXMD Outreach to Individual Pharmacies

>400 Pharmacies with Prescription Data

>500,000 prescriptions annually

*Formerly known as Premier Value Pharmacy Compounding Network

USP <800> Expenses Create Large Barriers for Compounders

USP <800> Requirements	Cost	Implementation Time
Segregated Clean Room: <ul style="list-style-type: none">USP <800> DesignConstruction	\$60,000 - \$200,000	1 year – 1.5 years
Ventilation System	\$25,000 - \$50,000	
New Equipment for Hazardous Compounding	\$15,000 - \$50,000	-
Total	\$100,000 - \$300,000	1 year – 1.5 years

- High upfront capital expenditures required for compliance
- Long implementation time
- Increased ongoing operating expenses associated with capital expenditures

Economic Incentives Provide Catalyst to Switch to TX-001HR

Economic Support TXMD Partnership for Patient Care

	Insurance Coverage (before 2H14)	Present Day (2018)	Post USP <800> (Dec. 2019)	TX-001HR Launch 1Q2019
Revenue				
Patient Co-Pay	\$50.00	\$50.00	\$50.00	\$50.00
Third-Party Reimbursement	\$115.00	-	-	\$200.00
Total Net Revenue	\$165.00	\$50.00	\$50.00	\$250.00¹
Costs of Good Sold	\$7.50	\$7.50	\$7.50	\$200.00 ²
Gross Profit	\$157.50	\$42.50	\$42.50	\$50.00
<i>Gross margin</i>	<i>95.5%</i>	<i>85.0%</i>	<i>85.0%</i>	<i>20.0%</i>
Operating Expenses				
G&A	\$15.00	\$15.00	\$15.00	\$15.00
S&M	\$7.50	\$7.50	\$7.50	\$5.00
Additional Compounding Costs ¹	\$15.00	\$15.00	\$15.00	-
<i>Cost of USP <800> Requirements²</i>	-	-	<i>\$10.00</i>	-
Total Operating Expenses	\$37.50	\$37.50	\$47.50	\$20.00
Pre-Tax Profit	\$120.00	\$5.00	\$(5.00)	\$30.00

1) Includes additional labor, pharmacists, technicians, regulatory, and legal expenses

2) December 2019 Implementation; includes >\$150,000 capital expenditure as well as new identification requirements for receipt, storage, mixing, preparing, compounding, dispensing, and administration of hazardous drugs



Annovera™

(Segesterone Acetate/Ethinyl Estradiol Vaginal System)

Approved for use by females of reproductive potential to prevent pregnancy. (Limitation of use: Not adequately evaluated in females with a body mass index of >29 kg/m²).

TherapeuticsMD®

For Her. For Life.

Annovera - 1-Year Vaginal System

First and only **patient-controlled, procedure-free, long-acting, reversible** birth control

- Annovera approved on August 10, 2018
 - Segesterone acetate component of Annovera classified as NCE with 5 year exclusivity
- Developed by the Population Council – developer of multi-billion dollar long acting contraceptive products
 - **ParaGard®** and **Mirena®** IUDs; **Norplant®** and **Jadelle®** implants; and **Progering®**
- Benefits
 - Increase compliance over short acting products
 - Offer women a long-term birth control option without requiring a procedure for insertion and removal like IUDs or implants
 - Allow women who haven't had a child (nulliparous) or are not in a monogamous relationship - who are often counseled against IUDs due to the potential risk of infertility - access to long-term reversible birth control


¹ Merkatz, Ruth B., Marlena Plagianos, Elena Hoskin, Michael Cooney, Paul C. Hewett, and Barbara S. Mensch. 2014. "Acceptability of the Nestorone®/ethinyl estradiol contraceptive vaginal ring: Development of a model; implications for introduction," *Contraception* 90(5): 514–521.

² Narender Kumar, Samuel S. Koide, Yun-Yen Tsong, and Kalyan Sundaram. 2000. "Nestorone: a Progestin with a Unique Pharmacological Profile," *Steroids* 65: 629-636

Annovera - 1-Year Vaginal System

Segesterone Acetate [Nestorone®]/Ethinyl Estradiol

- The vaginal system is composed of a “squishy” silicone elastomer
 - 21/7 days cyclical dosing regimen for one year (13 cycles)
 - 89% overall patient satisfaction in clinical trials¹
- Average daily release over one year of use:
 - 0.15 mg/day segesterone acetate
 - 0.013 mg/day ethinyl estradiol
- Nestorone: progesterone derived unique progestin²
 - High progestational potency and anti-ovulatory activity
 - No androgenic, estrogenic or glucocorticoid effects at contraceptive doses
- Strong safety and efficacy data
- High patient satisfaction and acceptability



¹ Merkatz, Ruth B., Marlena Plagianos, Elena Hoskin, Michael Cooney, Paul C. Hewett, and Barbara S. Mensch. 2014. "Acceptability of the Nestorone®/ethinyl estradiol contraceptive vaginal ring: Development of a model; implications for introduction," *Contraception* 90(5): 514–521.

² Narender Kumar, Samuel S. Koide, Yun-Yen Tsong, and Kalyan Sundaram. 2000. "Nestorone: a Progestin with a Unique Pharmacological Profile," *Steroids* 65: 629-636

Clinical Trial Experience

Efficacy & Safety¹

- **Based on two pivotal Phase 3 clinical trials with 2,308 women**
 - Efficacy and safety consistent with other birth control pills, patches and hormonal rings
- **Efficacy**
 - Highly efficacious in preventing pregnancy when used as directed (97.3%)
 - Primary Endpoint Pearl Index was 2.98 per 100 woman-years
 - Consistent with all other combination hormone birth control pills, patches and rings
- **Safety**
 - Class labeling for combination hormonal contraceptives (CHCs)
 - All CHCs carry the boxed warning about cigarette smoking and serious cardiovascular events, particularly for women over age 35
 - The risk profile is consistent with other CHCs
 - The most common adverse reactions include headache, nausea/vomiting, vulvovaginal mycotic infections, abdominal pain, dysmenorrhea, vaginal discharge, UTIs, among others
 - The most common adverse reactions leading to discontinuation were:
 - Irregular bleeding (1.7%), headache (1.3%), vaginal discharge (1.3%), and nausea/vomiting (1.2%)

¹ <http://annovera.com/pi.pdf>

Phase 3 Acceptability Study

Demonstrated 1-Year Contraceptive Vaginal System High User Satisfaction

Acceptability Data¹

- Phase 3 acceptability study (n=905 subjects)
- Overall satisfaction 89% related to ease of use, side effects, expulsions/feeling the product, and physical effect during sexual activity
- High rates of adherence (94.3%) and continuation (78%)

Ease of inserting (N=905)	Ease of removing (N=905)	Ease of remembering CVR insertion (N=905)	Ease of remembering CVR removal (N=905)	No side effects reported on questionnaire (N=905)
90.8% (n=823)	88.2% (n=798)	87.6% (n=793)	85.2% (n=771)	81.8% (n=740)

¹Merkatz, Ruth B., Marlena Plagianos, Elena Hoskin, Michael Cooney, Paul C. Hewett, and Barbara S. Mensch. 2014. "Acceptability of the Nestorone®/ethinyl estradiol contraceptive vaginal ring: Development of a model; implications for introduction," *Contraception* 90(5): 514–521.

Annovera Key Clinical Attributes

Clinical Attributes

- Only FDA approved long-acting reversible birth control that doesn't require a procedure or repeat doctor's visit
 - Empowers women to be in control of their fertility and menstruation
 - Annovera is the only user-directed single 12-month birth control product
- Highly effective in preventing pregnancy when used as directed (97.3%)
- High patient satisfaction in clinical trials¹ (89% overall satisfaction)
- Low daily release of ethinyl estradiol (13 mcg)
- Only product with new novel progestin - segesterone acetate²
 - No androgenic, estrogenic or glucocorticoid effects at contraceptive doses
- Favorable side effect profile including low rates of discontinuation related to irregular bleeding (1.7%)
- Safety profile generally consistent with other CHC products, including boxed warning

Physical Attributes

- Softer and more pliable than NuvaRing
- Acceptable for women who haven't had a child (nulliparous) or are not in a monogamous relationship³
- "Vaginal System" – the only product in a new class of contraception with potential for \$0 co-pay
- Cost and convenience (pharmacy and doc visits)
- Does not require refrigeration by HCP

¹ Merkatz, Ruth B., Marlena Plagianos, Elena Hoskin, Michael Cooney, Paul C. Hewett, and Barbara S. Mensch. 2014. "Acceptability of the Nestorone®/ethinyl estradiol contraceptive vaginal ring: Development of a model; implications for introduction," *Contraception* 90(5): 514–521.

² Narender Kumar, Samuel S. Koide, Yun-Yen Tsong, and Kalyan Sundaram. 2000. "Nestorone: a Progestin with a Unique Pharmacological Profile," *Steroids* 65: 629-636


³ Lohr, et al. Use of intrauterine devices in nulliparous women. *Contraception* 95 (2017); 529-537

U.S. Prescription Contraceptive Market

- One of the largest therapeutic categories by script count
- ~ > \$5B U.S. net sales¹


Daily Oral Contraceptives

- OC's continue to lose market share to longer acting solutions such as IUDs, Implants and Rings



Long Acting Reversible Contraceptives

- IUDs and Implants are experiencing significant growth as the market shifts towards long-acting solutions




¹ IQVIA 2017, Company filings. Long acting reversible contraceptive market includes: Nexplanon/Implanon, Mirena family, Paragard and Liletta. Net sales as reported in company filings.

TherapeuticsMD[®]

For Her. For Life.

Top Contraceptive Products Based on Revenue



Large Established Ring Market

Annovera compared to existing NuvaRing and potential NuvaRing generic

- 1-year duration (vs. monthly)
- Soft, pliable, squishy (vs. semi-rigid ring body)
- 89% overall patient satisfaction in clinical trials¹
- High rates of adherence (94.3%) and continuation (78%)¹
- New/Lower hormones
 - New progestin segesterone acetate (vs. etonogestrel)
 - No androgenic, estrogenic or glucocorticoid effects at contraceptive doses²
 - 13 mcg ethinyl estradiol (vs. 15 mcg)
- No monthly hormonal burst from each new NuvaRing placed
- No refrigeration required by HCP
- Low discontinuation rates³
 - Annovera: Irregular bleeding 1.7%, headache/migraine 1.3%, vaginal discharge/infections 1.3%, nausea/vomiting 1.2%
 - NuvaRing: Device-related events 2.7%, mood changes 1.7%, headache (including migraine) 1.5% and vaginal symptoms 1.2%
- Less expensive ~\$1,400 for Annovera vs. \$2,013 for NuvaRing based on annual WAC price
- “Vaginal System”- a new class of contraception with potential for \$0 co-pay
- NuvaRing no longer actively promoted

¹ Merkatz, Ruth B., Marlena Plagianos, Elena Hoskin, Michael Cooney, Paul C. Hewett, and Barbara S. Mensch. 2014. “Acceptability of the Nestorone®/ethinyl estradiol contraceptive vaginal ring: Development of a model; implications for introduction,” *Contraception* 90(5): 514–521.

² Narender Kumar, Samuel S. Koide, Yun-Yen Tsong, and Kalyan Sundaram. 2000. “Nestorone: a Progestin with a Unique Pharmacological Profile,” *Steroids* 65: 629-636

³ Based on product Prescribing Information; not a head to head comparison

Unique Product Characteristics Should Lead to Good Payer Coverage

- Anticipate parity or discount pricing level ~\$1,400 annual WAC cost
 - 30% decrease to annual WAC of NuvaRing, reflects TXMD's responsible brand pricing
 - Allows for improved patient adherence and a potential decrease in unplanned pregnancies
 - Only one pharmacy fill fee per year (estimated savings of \$33 annually per patient)
 - No repeat office visit or procedure fees (several hundred dollars per patient)
 - Contains ethinyl estradiol and Nestorone[®], a new and unique progestin
 - "Vaginal System"- a new class of contraception with potential for \$0 co-pay

The Affordable Care Act (ACA) mandates that private health plans provide coverage for one treatment per class of contraception used by women with no patient out-of-pocket costs

1-Year Vaginal Contraceptive System Serves an Unmet Need in the U.S. Contraceptive Market

	Annovera™	NuvaRing®	IUD's	Oral Contraceptives
Duration of Action	✓ 1 year (21/7 regimen)	✗ 1 month (21/ 7 regimen)	✓ 3-10 years	✗ Daily pill intake
Patient Control	✓ Removable at any time	✓ Removable at any time	✗ Procedure required	✓ Stop at any time
Nulliparous Women	✓ Yes	✓ Yes	✗ Not universally acceptable	✓ Yes
Product Administration	✓ Patient administered pliable ring	✓ Patient administered Semi-rigid ring	✗ Physician in-office procedure	✓ Oral intake
Patient Convenience	✓ 1 doctor's visit, 1 pharmacy visit per year	✗ Monthly pharmacy visit	✗ Physician in-office procedure HCP stocking required	✗ Daily pill presents compliance/adherence risks; potential increase in unplanned pregnancies
Healthcare Provider Convenience	✓ Filled at pharmacy; No refrigeration; No inventory or capital outlay	✓ Filled at pharmacy; Refrigeration required prior to being dispensed	✗ HCP required to hold inventory	✓ Filled at pharmacy
Cost	✓ \$1,400 WAC	✗ \$154.89/28 days, or 1 year cost of \$2013.57 (13 rings/year)	✓ \$909 WAC + insertion and removal costs (good for 5 years)	✗ Lo Loestrin® Fe \$128.51/28 days, or 1 year cost of \$1,670.63 (13/year)
Contraceptive Class	Vaginal System	Vaginal Ring	IUD	Oral

- ✓ 89% overall patient satisfaction in clinical trials, 94% adherence rate, 78% continuation rate
- ✓ "Vaginal System"- potential for a new class of contraception with \$0 co-pay
- ✓ Segesterone acetate component of Annovera classified as NCE with 5 year exclusivity

Chart comparisons for product characteristics only and are not intended to imply safety or efficacy comparisons

TherapeuticsMD®

For Her. For Life.

Commercialization Strategy

Launch Timing

- Estimated to be commercially available as early as Q3'19 with commercial launch as early as Q4'19 to Q1'20

Attractive Market Segments for Annovera

- NuvaRing users – leveraging the physical and clinical strengths of Annovera
 - No additional sales representatives needed
 - 81% of total prescribers within current 150 TXMD territories¹
- Women who want long-acting reversible contraception but don't want a procedure
- Providers who do not want to purchase and manage inventory of IUDs and implants
- Women who haven't had a child (nulliparous) or are not in a monogamous relationship and want long-term contraceptive options

¹ IQVIA Data

Complete Women's Healthcare Portfolio



Annovera™

TX-001HR*

Imvexxy™
(estradiol vaginal inserts)
4 mcg - 10 mcg



**~60,000
New Prenatal
Patients**
*Many will go on
contraception after
breastfeeding*



**Vasomotor
symptoms affect
up to 75% of
perimenopausal
women¹**



PRENATAL CARE

**CONTRACEPTION/ FAMILY
PLANNING -PERIMENOPAUSE**

VASOMOTOR SYMPTOMS

**DYSPAREUNIA
(Vulvar & Vaginal Atrophy)**

REPRODUCTIVE HEALTH

MENOPAUSE MANAGEMENT


*Investigational product, pending FDA approval

1. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4539866/>

TherapeuticsMD®

For Her. For Life.

Contraceptive Pipeline



Exclusive rights to negotiate co-development and marketing rights¹

- 3 month ring using NES plus bio-identical Estradiol (E2) (Phase 2)
- 1 year contraceptive vaginal system (NES/EE) life cycle management

¹TXMD has the option to co-develop and market in the US, if approved

Committed to Become the Leading Women's Health Company



TherapeuticsMD®

For Her. For Life.

TherapeuticsMD, A Premier Women's Health Company

Annovera™

 vitaMedMD®

Annovera™

TX-001HR*

 Imvexxy™
(estradiol vaginal inserts)
4 mcg - 10 mcg





CONTRACEPTION

PRENATAL CARE

CONTRACEPTION/
FAMILY PLANNING -
PERIMENOPAUSE

VASOMOTOR
SYMPTOMS

DYSPAREUNIA
(Vulvar &
Vaginal Atrophy)



REPRODUCTIVE HEALTH

MENOPAUSE MANAGEMENT

*Investigational product, pending FDA approval

TherapeuticsMD®

For Her. For Life.

Significant Insider and Institutional Share Ownership

- Board of Directors and Executive Officers have long-term commitment to the company
 - Beneficially own approximately 21% of the company's shares
 - Three founding executives beneficially own approximately 17% of the company's shares
 - Includes vested options to acquire approximately 5 million shares of common stock (approximately 11% of such executives' current beneficial ownership) that were originally issued on January 1, 2009 and expire on January 1, 2019
- Large institutional holder support
 - Large institutional holders – many long-term – beneficially own more than 55% of the company's outstanding shares

TXMD: Financial Snapshot

**Listing
Exchange**



**Insider
Ownership**

~21%

(Post-offerings Aug 6, 2018)

**Shares
Outstanding**

235.4M

(Post-offerings Aug 6, 2018)

Debt

\$75M

(as of June 30, 2018)

Cash

\$154.4M

(as of June 30, 2018)

**Net Cash
Raised in
Aug Offerings**

\$90M

TherapeuticsMD[®]

For Her. For Life.

A woman with dark hair, wearing a light green sweater, is laughing heartily. She is leaning over a man who is sitting in a white chair. She has her hands over his eyes, and he is also laughing. The background is a soft-focus indoor setting with a window. The overall mood is joyful and intimate.

Thank You

TherapeuticsMD[®]

For Her. For Life.